Establishment Labs (NASDAQ:ESTA) Announces Earnings Results, Misses Estimates By $0.05 EPS

Establishment Labs (NASDAQ:ESTA) posted its quarterly earnings results on Thursday. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.05), FiscalAI reports. The business had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. Establishment Labs had a negative return on equity of 218.77% and a negative net margin of 19.05%.The business’s revenue was up 31.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.57) earnings per share.

Here are the key takeaways from Establishment Labs’ conference call:

• Positive Sentiment: Q2 revenue rose 31.7% year over year to $67.5 million, led by U.S. revenue growth of 140.9% to $24.7 million. Management raised full-year revenue guidance to $269 million-$271 million.
• Positive Sentiment: U.S. adoption of Motiva continued to accelerate, surpassing 100,000 implants and 2,000 customer accounts in under 21 months. Increasing utilization within existing accounts and growing patient requests for Motiva are supporting momentum.
• Positive Sentiment: The minimally invasive platform generated $12.1 million in Q2 revenue and is expected to approach 15% of full-year revenue. Preservé training exceeded expectations with more than 300 certified U.S. surgeons, while the company expects to train approximately 500 during 2026.
• Positive Sentiment: Profitability and cash generation improved substantially, with gross margin expanding to 70.6% and adjusted EBITDA turning positive at $3.7 million versus a prior-year loss of $8.5 million. Management expects to become free-cash-flow positive in the second half of 2026 and for fiscal 2027, without needing additional equity raises.
• Negative Sentiment: The third quarter is expected to reflect normal seasonal weakness, with the fourth quarter typically strongest. Middle East distributor demand has fallen because of regional conflict and is expected to remain depressed for the rest of the year, although the region represents less than 5% of revenue.

Establishment Labs Trading Down 13.4%

NASDAQ ESTA traded down $12.20 on Thursday, reaching $79.05. The stock had a trading volume of 1,151,900 shares, compared to its average volume of 456,844. The firm has a market capitalization of $2.33 billion, a price-to-earnings ratio of -53.05 and a beta of 1.07. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82. Establishment Labs has a 12-month low of $33.35 and a 12-month high of $97.59. The stock has a fifty day moving average price of $86.29 and a two-hundred day moving average price of $74.23.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Quarry LP purchased a new stake in shares of Establishment Labs in the 3rd quarter valued at $34,000. Kestra Advisory Services LLC purchased a new position in Establishment Labs during the 4th quarter valued at about $47,000. Osaic Holdings Inc. boosted its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares during the period. PharVision Advisers LLC purchased a new position in Establishment Labs during the 3rd quarter valued at about $203,000. Finally, Twinbeech Capital LP acquired a new position in Establishment Labs in the 4th quarter valued at about $214,000. 72.91% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Establishment Labs

Here are the key news stories impacting Establishment Labs this week:

• Positive Sentiment: BTIG Research raised its price target to $103 from $96 and maintained a “buy” rating, implying substantial upside from the referenced share price. Benzinga article
• Positive Sentiment: Needham increased its price target to $95 from $86 and reiterated a “buy” rating, signaling continued analyst confidence in Establishment Labs’ growth outlook. StreetInsider article
• Positive Sentiment: Second-quarter revenue increased 31.7% year over year to $67.54 million, exceeding analysts’ $65.79 million estimate. The company also projected fiscal 2026 revenue of $269 million to $271 million, above the $267.5 million consensus forecast. Zacks article
• Neutral Sentiment: Management discussed the quarter and outlook during the Q2 2026 earnings call, providing additional context for investors evaluating the company’s growth plans and path toward profitability. Q2 2026 earnings call transcript
• Negative Sentiment: Establishment Labs reported a $0.39 quarterly loss per share, wider than the expected $0.34 loss, although it improved from a $0.57 loss in the prior-year quarter. Ongoing losses and negative profitability metrics likely weighed on the stock.

Analyst Ratings Changes

A number of research firms have weighed in on ESTA. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Wednesday, June 24th. Needham & Company LLC upped their price target on Establishment Labs from $86.00 to $95.00 and gave the company a “buy” rating in a research report on Thursday. Canaccord Genuity Group set a $105.00 price target on Establishment Labs in a report on Thursday. Citigroup lifted their price objective on Establishment Labs from $76.00 to $92.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. Finally, BTIG Research boosted their price objective on Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a research note on Thursday. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $98.38.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.